Release Date: February 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you comment on the progress of the Rezdiffra launch and any notable trends in the first two months of 2025? A: Bill Sibold, CEO: The momentum from 2024 has carried into 2025, with steady additions of patients and prescribers. We are managing the typical Q1 dynamics well, and there is no prescriber yet maxed out on patients. We continue to add new prescribers, reaching 60% penetration into our target group.
Q: Could you elaborate on the clinical significance of the 6.7 kilopascal reduction in liver stiffness for F4 cirrhotic patients? A: Michael Charlton, SVP Clinical Development: A 6.7 kilopascal reduction, starting from a baseline of 25 kilopascals, is highly predictive of decreased risk of clinical outcomes. This reduction suggests a significant move into a lower risk category for liver-related events.
Q: Will Madrigal provide guidance for 2025, and how do you view consensus estimates? A: Mardi Dier, CFO: We are not providing specific guidance at this time due to the early stage of the launch. However, we are pleased with the momentum going into 2025 and expect consensus for Q1 and the full year to narrow and increase slightly based on current trends.
Q: How do you view the potential impact of GLP-1 therapies on Rezdiffra's market position? A: Bill Sibold, CEO: We believe GLP-1 therapies will expand the market, benefiting Rezdiffra as the leader. Our product's profile, ease of use, and rapid efficacy make it the preferred choice for patients with severe liver disease. We expect to maintain our leadership position despite new entrants.
Q: What are the challenges and strategies for launching Rezdiffra in Europe? A: Bill Sibold, CEO: We will approach Europe on a country-by-country basis, aiming for positive contribution within two to three years. We believe in the value of Rezdiffra and will engage in discussions with each country to support favorable pricing. Our strategy is to pursue markets where the value of Rezdiffra is recognized.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。